Lenvatinib Mesylate
| CAS No. | 857890-39-2 |
|---|---|
| MDL No. | MFCD18633219 |
| MF | C22H23ClN4O7S |
| MW | 523.00 |
| InChI Key | HWLFIUUAYLEFCT-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Lenvatinib mesylate is the methanesulfonate salt of lenvatinib, formed by reaction with one molar equivalent of methanesulfonic acid. It is a multi-kinase inhibitor and orphan drug, used in the treatment of thyroid cancers resistant to radioiodine. It functions as an EC 2.7.10.1 inhibitor, fibroblast growth factor receptor antagonist, vascular endothelial growth factor receptor antagonist, and antineoplastic agent. It contains lenvatinib(1+).
| CAS No. | 857890-39-2 |
|---|---|
| Product Name | Lenvatinib Mesylate |
Biological Targets
FLT1·FLT4·KDR
Associated Conditions
intrahepatic cholangiocarcinoma·follicular thyroid carcinoma·cancer·thyroid carcinoma·kidney cancer·
* The information provided here is compiled from public sources and is for reference only.
